 DS in Africa is underdiagnosed due to lack of awareness, epilepsy research and access to genetic testing.  SCN1A variants underlie disease in the majority of South African DS patients  SCN1A-associated DS was shown as highly probable in children with seizure onset before 6 months of age, as well as a clinical DS risk score of >6.  In resource-limited settings, these simple diagnostic tools can assist in the choice of treatment and alert to the need for specialist consultation and genetic testing.
A C C E P T E D M A N U S C R I P T
INTRODUCTION
Dravet syndrome (DS) (OMIM 607208), previously described as severe myoclonic epilepsy of infancy (SMEI) is a severe genetic epilepsy with associated encephalopathy. [1] Early clinical presentation of DS is characterised by the onset of prolonged, febrile and afebrile generalized clonic or hemiclonic seizures in an otherwise normally developing infant. Seizures are usually resistant to typically prescribed anti-epileptic drugs (AEDs) and evolve with the disease progression to include myoclonic, atypical absences and focal seizures. After this initial phase, the clinical presentation becomes less distinctive and the opportunity to recognize the condition early may be missed. Life-threatening episodes of status epilepticus (SE), seizure-related accidents and sudden unexpected death in epilepsy (SUDEP), all contribute towards a significantly increased premature mortality among individuals with DS. [2, 3] An important reason for early recognition of DS, is the contraindication of treatment with sodium channel inhibitors (e.g. carbamazepine, oxcarbazepine, lamotrigine), as this may worsen the condition. [4, 5] Other contraindications include chronic use of benzodiazepine (BZ), which may facilitate encephalopathy and resistance to BZ administered for status epilepticus (SE). [6] DS progresses in three stages: the first diagnostic "febrile stage" is marked by frequent, prolonged febrile seizures in the first year of life; the second "worsening stage" occurs between the ages of 1 and 5 years with frequent seizures and episodes of status epilepticus, behavioral deterioration and neurological signs, followed by the third "stabilization stage" characterized by a decrease in convulsive seizures which occur mainly during sleep. During this last stage, seizures continue to impact on the child's quality of life, though myoclonic and absence seizures may disappear. Neurological development may improve but a variable degree of cognitive impairment persists, often with challenging behavioural issues. Ataxia and gait problems become a major concern. [1] At present, the realistic objective of treatment is cessation of prolonged seizures, reduced seizure frequency and cognitive and motor sequelea. [6] The degree of success however, is wholly dependent on early correct diagnosis and appropriate intervention.
A C C E P T E D M
A N U S C R I P T Over 80% of DS cases are associated with de novo variants in the SCN1A gene (OMIM 182389), which encodes the alpha subunit of the sodium ion channel. [1] The majority of the remaining DS patients do not carry currently identifiable variants, though some children harbour pathogenic variants in other ion and non-ion channel genes. [7] This relative genetic homogeneity holds DS apart from most other EEs, which are highly genetically heterogeneous. [8, 9] Careful clinical correlation is important, as SCN1A variants are also found in other severe epilepsies (e.g. epilepsy of infancy with migrating focal seizures (EIMFS) [10] , as well as less severe epilepsy phenotypes such as familial febrile seizures (FS), [11] or genetic epilepsy with febrile seizures plus (GEFS+). [12] The factors predicting long-term developmental outcome remain unclear but an early diagnosis and seizure control may delay or prevent the onset of EE and mitigate the outcomes. [5, 13] The incidence of DS in high income countries (HICs) is estimated to range between 1 in 15 700 and 1 in 40 900 live births [1] . At present, the incidence of DS in Africa is unknown, due to virtual absence of genetic testing or epilepsy research. However, given that most SCN1A variants arise de novo, we expect the incidence of DS in Africa to reflect that of international studies. Whilst Africa, particularly sub-Saharan Africa (SSA), bears the highest burden of epilepsy in the world, [14] genetic epilepsy is among the most underdiagnosed and underinvestigated disorders on the continent. In a setting where seizures are frequently a result of endemic parasitic disease, central nervous system (CNS) infections, traumatic brain injury or perinatal insults, a diagnosis of a genetic epilepsy is rarely considered. Acute symptomatic seizures and febrile seizures are frequently assumed to be due to malaria, limiting the search for other causes [15] . Lack of awareness, limited specialist expertise, suboptimal health infrastructure and unavailability of diagnostic testing all contribute towards this void in knowledge and medical care. The extensive evidence of the genetic contribution to many epilepsy phenotypes, and the clinical utility of testing, especially relevant to early-life epilepsies, has informed the diagnostic laboratory protocols of many HICs. [16] [17] [18] . It is important to ensure that African patients also benefit from this knowledge and that new knowledge is gained through research on the highly genetically diverse populations of Africa. [19] In this study, we collected clinical and clinico-electrical information and performed genetic testing on a cohort of 22 South African infants diagnosed with Dravet or Dravet-like syndromes. Our main aim was characterization of the genetic landscape of DS in South Africa (SA) for the purpose of drawing up clinical and molecular diagnostic protocols for early, cost-effective diagnosis of DS in the local setting, including retrospective cascade counselling and patient follow-up. To our knowledge, this is the first report correlating phenotypic and genetic aspects of DS in Africa.
METHODOLOGY

Cohort Recruitment
Infants with provisional clinical diagnoses of DS were recruited over a period of six months by clinicians affiliated to or working in the Paediatric Neurology service at the Red Cross Children's War Memorial Hospital (RCCWMH) in Cape Town. The patients were referred to the Epilepsy Clinic at the 
Genetic Analysis
Genomic DNA was isolated from peripheral blood (2-5ml) of the probands and parents (where available). DNA isolation and the integrity checks were performed using standard methods (NanoDrop™1000 and, Qubit ® dsDNA HS (High Sensitivity) Assay, ThermoFisher Scientific, USA).
The cohort was initially tested locally (Division of Human Genetics, University of Cape Town (UCT)), where the Ion Torrent™ PGM platform (ThermoFisher Scientific) was used to resequence six genes previously reported to carry pathogenic variants in children with DS (SCN1A, GABRA1, GABRG2, STXBP1, HCN1 and PCDH19) (refs) . The AmpliSeq™ Designer Software v4.47 (ThermoFisher Scientific, USA) was used to design two pools of primers for a total of 161 amplicons, predicted to capture 99,08% of all the coding exons (with 100% capture for the SCN1A gene specifically), each flanked by ten bases of intronic sequence (RefSeq. hg19 build), to be sequenced at a minimum 100x depth of coverage. The NGS library was prepared on the Chef DL8 using the Ion AmpliSeq™ Kit (ThermoFisher Scientific, USA) according to the manufacturer's protocol. Basic NGS quality assessment, read alignment, variant identification, annotation, prioritisation, and filtering was performed by the Ion Reporter™ cloud-based software (ThermoFisher Scientific, USA). The VCF files were then used for further manual variant filtering and prioritisation. Only nonsynonymous, splice-site and frameshift variants not found in the ExAC v0.3, ESP6500 or 1000 Genomes databases were assessed further. [21] [22] [23] All putative variants were confirmed by Sanger sequencing. Segregation analysis was done in all cases where parental samples were available. All variant-negative samples were tested with the multiple ligase-dependent probe amplification (MLPA) assay for exonic deletions/duplications in the SCN1A gene (P137-B2 probe mix, MRC-Holland).
To validate our findings on the Ion Torrent™PGM system, the DS cohort was re-tested on the Illumina HiSeq™ platform at the University of Washington (Seattle, USA), as part of a larger project investigating the genetic causes of EEs in South African patients (ongoing). The single molecule Molecular Inversion Probe (smMIP) technology was employed as previously described [24] to capture all exons and intron-exon boundaries (5-bp flanking sequences) of the target genes at capture, including SCN1A, GABRA1, GABRG2, STXBP1, HCN1 and PCDH19 (RefSeq, hg19 build). [25] Sequencing was performed at 98% capture and 40X minimum depth of coverage. NGS quality
assessment, read alignment, depth of coverage, variant identification, annotation, prioritisation, and filtering was also performed using previously published methods. [25] [26] [27] The VCF files were then subject to further manual variant filtering and prioritisation.
Pathogenicity assessment of variants
Only nonsynonymous, splice-site and frameshift changes were considered for pathogenicity assessments ( Table 2) . Variants were classified according to the interpretation guidelines from the American College of Medical Genetics and Genomics-Association for Molecular Pathology (ACMG-AMP). [28] Briefly, a variant was classified as likely/pathogenic if it arose de novo (or from a somatic mosaic parent) and was not found in the publically available control datasets (ExAC v0.31, ESP6500, 5000 Genomes, gnomAD r2.0.2). [21] [22] [23] In cases where DNA from both parents was unavailable for segregation analysis, likely/pathogenicity was inferred on the basis of (1) the variant type (truncations and splice variants were seen as likely pathogenic), (2) recurrence (previously recorded as diseasecausing in the literature or disease databases (3) analysis with in silico pathogenicity prediction tools (CADD, PolyPhen-2, and GERP), where all outputs had to be in agreement (CADD > 25, PolyPhen-2 > 0.9, and GERP > 5). Microsatellite analysis (Authentifiler™ PCR Amplification kit, ThermoFisher Scientific) was performed on of all parents of probands with a de novo variants to confirm parentage.
Clinical data assessment
Clinical demographics, seizure semiology, seizure evolution and treatment history were collected both prospectively and retrospectively by clinical assessment, parent/guardian interview and review of patient records (Table 3) . A clinical risk score for progression to DS after an initial complex febrile seizure described by Hattori et al (2008) , was determined for each patient. [29] The score takes into account the age at seizure onset, total number of seizures before one year of age, total number of prolonged seizures (longer than 10 minutes), and the seizure type and trigger ( Table 1 ). The clinical score was then compared to the clinician's level of confidence in the diagnosis of DS: definitely compatible with DS or possible DS. It was also correlated with the presence/absence of an SCN1A variant.
Statistical analysis
Statistical comparison of the clinical demographics, seizure semiology, seizure evolution and treatment history was made between the group of patients with SCN1A variants and the group with no identified variants (Table 3 ), using R [30] . This was intended to highlight any possible statistically significant associations between specific clinical features, and the presence/ absence of an SCN1A variant. Fisher's exact test was used where there were two nominal variables. To permit nonparametric analysis of the two groups without assuming normal distribution of values the MannWhitney U test was used for other parameters.
RESULTS
Genetic analysis
Pathogenic changes were found in 10 out of 22 patients: nine carried SCN1A variants (four missense, three frameshift and two nonsense) and one female carried a heterozygous nonsense variant in the PCDH19 gene. The specific coverage achieved for the coding region of the SCN1A gene (26 exons) was 100% capture and a >100X depth of coverage on Ion Torrent and >40X unique capture with smMIPs. De novo variants could be shown in only five patients, as DNA from both parents was not available in the remaining cases (Table 2) .
Statistical analysis
The key findings in the two main groups, namely, the SCN1A-positive group (n=9) and the variantnegative group (n=12), are summarised in Table 3 Regarding interventions, the SCN1A-postitive group was more likely to receive a combination of AEDs (eight out of nine SCN1A-positive patients), whilst 11 out of 12 variant-negative children were managed effectively with monotherapy. No significant differences between the two groups were noted in the median number of AEDs trialed or the degree of seizure control achieved. Whilst there was no difference in the developmental function before seizure onset, developmental delay was more likely in the SCN1A-positive group after seizures onset. Similar findings were noted for subsequent speech, behaviour and features of the Autism Spectrum Disorder (ASD), based on neurodevelopmental assessments. The SCN1A-positive children were significantly more likely than the variant-negative group to require ancillary support and to be placed in special-needs schools. They were also better attendees to the Neurology service, with more frequent hospital visits related to the challenges of managing intractable seizures and the associated complications.
Long term follow-up enabled clinical reassessment of the variant-negative group with a revised diagnosis in ten patients: seven were re-diagnosed with febrile seizures plus (FS+) and one with early onset epileptic encephalopathy (EOEE). Perinatal insult and moyamoya disease were determined as the cause of seizures in the remaining two cases. It was also noted that out of 11 Indigenous Black African children included in our study (45% of the cohort), only one carried a SCN1A variant Also, closer scrutiny of the clinical demographics showed that the median clinical score among the variant-negative indigenous black African children was six (range 0 -8), and the median age of onset was 12 months (range 3 -17 months) (not included in Table 3 ).
DISCUSSION
We have described the results of the first genetic study of DS in Africa. Despite the small cohort size, our findings carry significant implications for the diagnosis and management of children with DS in SA, and perhaps more broadly in Africa. Although the clinical features and genetic underpinnings of DS in our cohort were not novel, identification of nine patients carrying pathogenic or likely pathogenic SCN1A variants (41% of the cohort) and one female patient with a pathogenic PCDH19 variant, confirmed that the genetic aetiology of DS in our region is similar to that in other international study cohorts. However, compared to the published studies, the proportion of SCN1A-positive DS in our cohort appeared low (41%), raising a concern about missed variants. [5, 6] This proved unlikely, as the SCN1A coding region (26 exons) was covered at 100% capture and a good depth of coverage (>100X on Ion Torrent and >40X unique capture with smMIPs). Most importantly, our local NGS findings obtained with a custom panel on the Ion Torrent™PGM platform were confirmed with the published smMIPs technology [25] on the Illumina HiSeq in the USA, validating NGS in our hands for translation into the diagnostic setting. Subsequently, the diagnosis of DS was revised for 10 of the 12 variantnegative patients (seven FS+, one EOEE, one moyamoya disease and one perinatal insult), increasing our proportion of SCN1A-positive DS 75%, more in line with international findings. The relatively high number of patients re-diagnosed with FS+ was a likely consequence of the broad inclusion criteria of infantile-onset recurrent complex febrile seizures with normal prior development, which enhanced recruitment but also resulted in inclusion of the non-Dravet, FS+ phenotypes.
Statistical analysis of the clinical demographics highlighted the DS risk score and the age at seizure onset as the most useful clinical diagnostic markers for DS. The DS risk scoring system, devised by Hattori and colleagues, compared the clinical characteristics of Japanese Dravet and non-Dravet patients with seizure onset before one year of age. [29] In our cohort, the median score in the SCN1A-positive group (median score 9.00, range 8.00 -11.00) was significantly higher than that in the variantnegative group (median score 5.50, range 3.75 -6.00). This was in agreement with Hattori and colleagues, who proposed that a child with a score of six or higher was at an increased risk of DS and should undergo SCN1A testing. [29] However, the utility of this scoring system may be limited in the African context, as recognition of some of its diagnostic markers e.g. hemiclonic seizures (not usually seen in the earliest presenting period of DS), requires some experience in child neurology and epilepsy. In the African setting, where many of these children are initially seen by primary healthcare workers, straightforward clinical indicators are needed to prompt early referral to specialist centres.
The significantly earlier median age of onset in the SCN1A-positive children in our study (4 The low number of SCN1A-DS among the indigenous black children in our cohort (only one of 10), prompted a clinical reassessment, resulting in a revised diagnosis for nine patients, the majority of whom fell into the FS+ category. These children were more likely to be based in poorer socioeconomic settings, often with multiple healthcare challenges and at risk of recurrent infections, placing this group at an increased risk of recurrent FS. The results of our study therefore emphasise the importance of genetic testing not only for the variant-positive patients but also the patients in whom negative test results precipitate clinical reassessment and a revised diagnosis.
Investigators in a recent epidemiological study of DS in the United States (US) found that clinical DS in the US occurs at an incidence of 1 in 15 700 births and is more than twice as common as previously reported. [34, 35] The US study also reported a higher incidence of SCN1A-associated DS (1 in 20 900 births), compared to the European estimates ranging from 1 in 22 000 to 1 in 41 000. [13, 36] figure) . It is therefore likely that many DS patients in the Western Cape and across SA are not diagnosed or managed appropriately. Most of these children could now be clinically recognized using the age of onset and the DS risk scoring system, [29] and referred for genetic testing.
Our findings are new and especially useful in the African context, where genetic epilepsy research is limited and diagnostic testing is not available. The correct diagnosis and treatment of DS and other epileptic encephalopathies may be achieved months or years after initial presentation, if at all. The DS risk score and age of onset of prolonged febrile seizures before 6 months of age present quantitative low-cost criteria to identify patients most at risk of DS and who are likely to benefit from genetic testing. [29, 31] Whilst the scoring system may be more relevant to patients with established DS beyond the early febrile stage, the age at seizure onset is a simple clinical marker for early DS. In the poorest and most remote rural regions, such simple diagnostic tools can assist in the choice of treatment and alert to the need for specialist consultation and genetic testing.
As a direct result of this study, the Epilepsy Clinic at the RCWMCH now has nine patients with confirmed SCN1A-associated DS, and one patient with PCDH19-related epilepsy on its records.
These findings highlighted the sometimes underestimated diagnostic precision of an informative genetic test result in a child with possible DS. Anecdotally, the appreciation of "diagnostic closure" was strongly expressed by the parents and clinicians alike, also emphasizing the role of genetic counselling. Understanding the cause of the disease in a child brought about a sense of relief, acceptance and a more focused approach to care. Whilst the management typically followed the available interventions recommended for DS, including valproate and clobazam, following the genetic confirmation parents were more committed to accessing stiripentol and trials of the ketogenic diet. The study outcomes also presented a potential focus for future research towards identifying the causes of genetic and clinical heterogeneity in the "variant-negative" patients of our cohort.
Conclusion
DS is, arguably, the most extensively studied epileptic encephalopathy (EE) [6] and also one of the most clinically challenging epilepsy syndromes. The intractable seizures, multiple co-morbidities and constant threat of premature mortality profoundly affect the quality of life of the children and their families. A better outcome can be achieved with appropriate intervention and more targeted therapy at an early stage of the disease, reflecting an example of precision medicine. [39] This is the first study investigating the genetic causes of DS in SA. Whilst conclusions drawn from small cohorts are generally viewed with caution, our results, as a snapshot of DS in the local population, confirm that de novo SCN1A variants are associated with disease in the majority of South African DS patients. Adding to the molecular findings, a significant outcome of this study was affirming the link between the DS risk score, the age at seizure onset and the presence of an SCN1A variant. In the poorly resourced African setting, observing these clinical signs of DS may go a long way towards embarking on the correct diagnostic course for DS and a better overall outcome. This also highlights the importance of raising awareness among healthcare practitioners of a possible genetic contribution to the seizure pathogenesis in their patients, thus beginning to bridge the significant epilepsy treatment gap in Africa.
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